Key result
An intravenous chelation regimen with disodium EDTA modestly reduced the risk of adverse cardiovascular outcomes compared with placebo (26% vs 30%; HR 0.82; 95% CI 0.69-0.99; P=0.035).
Why the study?
Does an intravenous chelation regimen with disodium EDTA reduce cardiovascular events in stable patients with a history of MI?
Population
1708 patients aged 50 years or older who had experienced a myocardial infarction at least 6 weeks prior and…
Comparison
40 infusions of a 500-mL chelation solution… vs Placebo infusions administered on the same…
Design
RCT, 2 × 2 factorial randomized trial, Double-blind, placebo-controlled
Follow-up
median, 55 months
Authors
Loading...
May warrant consideration in select post-MI patients; extends chelation evidence but does not support routine use.
RCT (n=1,708)
Double-blind
2 × 2 factorial
Yes
Does an intravenous chelation regimen with disodium EDTA reduce cardiovascular events in stable patients with a history of MI?
Hazard Ratio: 0.82 (95% CI 0.69–0.99)
Absolute Event Rate: 26% vs 30%
p-value: p=.035
Intravenous chelation therapy with disodium EDTA modestly reduced the risk of adverse cardiovascular outcomes in stable patients with a prior MI, though the results are not sufficient to support routine clinical use.
Lamas et al. (2013) conducted an RCT in Previous myocardial infarction (n=1,708). Disodium EDTA chelation regimen vs. Placebo was evaluated on Composite of total mortality, recurrent MI, stroke, coronary revascularization, or hospitalization for angina (HR 0.82, 95% CI 0.69-0.99, p=.035). An intravenous chelation regimen with disodium EDTA modestly reduced the risk of adverse cardiovascular outcomes compared with placebo (26% vs 30%; HR 0.82; 95% CI 0.69-0.99; P=0.035).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: